W. Weng

Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment

J. Kawashima, Y. Xin, J. Silverman, 2018, Journal of clinical pharmacology.

Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection

S. Lewis, R. Mackman, P. German, 2018, Journal of clinical pharmacology.

Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers

R. Begley, A. Mathias, B. Kearney, 2020, Clinical pharmacology in drug development.

A Quantitative Framework to Evaluate Proarrhythmic Risk in a First‐in‐Human Study to Support Waiver of a Thorough QT Study

C. Garnett, S. Ramanathan, J. Lin, 2015, Clinical pharmacology and therapeutics.

The Drug–Drug Interaction Profile of Presatovir

Y. Xin, J. Chien, J. Silverman, 2018, Journal of clinical pharmacology.

Design and Analysis of Clinical Pharmacology Studies

Liang Fang, W. Weng, 2019, Statistical Methods in Biomarker and Early Clinical Development.

Biomarker Assay Development, Qualification, and Validation

Shuguang Huang, Cheng Su, Guang Chen, 2019, Statistical Methods in Biomarker and Early Clinical Development.